T. Rowe Price Investment Management
KYMR icon

T. Rowe Price Investment Management’s Kymera Therapeutics KYMR Stock Holding History

T. Rowe Price Investment Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718M Buy
6,257,261
+792,264
+14% +$68.1M 0.47% 46
2026
Q1 		$455M Buy
5,464,997
+4,835,252
+768% +$383M 0.31% 84
2025
Q4 		$49M Buy
629,745
+18,524
+3% +$1.25M 0.03% 366
2025
Q3 		$34.6M Buy
611,221
+520,593
+574% +$23.5M 0.02% 431
2025
Q2 		$3.96M Buy
+90,628
New +$3.12M ﹤0.01% 585
2024
Q1 		– Sell
-1,295,943
Closed -$33M – 639
2023
Q4 		$33M Sell
1,295,943
-314,553
-20% -$5.63M 0.02% 443
2023
Q3 		$22.4M Hold
1,610,496
– – 0.02% 467
2023
Q2 		$37M Sell
1,610,496
-357,679
-18% -$10.2M 0.03% 416
2023
Q1 		$58.3M Buy
1,968,175
+12,198
+0.6% +$393K 0.04% 345
2022
Q4 		$48.8M Sell
1,955,977
-40,552
-2% -$1.08M 0.04% 358
2022
Q3 		$43.5M Buy
+1,996,529
New +$52.6M 0.03% 364

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management's KYMR Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Kymera Therapeutics (KYMR) stake by 14% in Q2 2026, buying an estimated $68.1M and bringing the position to 6,257,261 shares worth $718M. The position accounts for 0.47% of the portfolio, ranked #46.

T. Rowe Price Investment Management first reported a position in KYMR in Q3 2022 and has held it in 11 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • T. Rowe Price Investment Management held 6,257,261 shares of Kymera Therapeutics worth $718M as of Q2 2026.
  • T. Rowe Price Investment Management bought 792,264 Kymera Therapeutics shares in Q2 2026, an estimated $68.1M.
  • Kymera Therapeutics made up 0.47% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #46 holding.
  • T. Rowe Price Investment Management first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.